Skip to content

Geron GERN Total debt

Total debt at other companies

Immunome logo
ImmunomeIMNM
$3.69M-22.6%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$350.49M+4.2%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$113M+88.3%
Celcuity logo
CelcuityCELC
$137.89M+30.7%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-7.6%
Enterprise value$973.78M-5.3%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Calculated from Geron’s reported figures.

Plus components not separately reported this period.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's total debt?
Geron (GERN) reported total debt of $133.99M in Q1 2026.
How has Geron's total debt changed year-over-year?
Geron's total debt increased by 10.0% year-over-year, from $121.78M to $133.99M.
What is the long-term trend for Geron's total debt?
Over 5 years (2020 to 2025), Geron's total debt has grown at a 32.6% compound annual growth rate (CAGR), from $29.72M to $121.99M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.